share_log

Reneo Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-OCTAGON CAPITAL ADVISORS LP(6.75%),OCTAGON INVESTMENTS MASTER FUND LP(6.75%), etc.

Reneo Pharmaceuticals | SC 13G：超過5%持股股東披露文件-OCTAGON CAPITAL ADVISORS LP(6.75%),OCTAGON INVESTMENTS MASTER FUND LP(6.75%)等

SEC announcement ·  02/05 16:05
Moomoo AI 已提取核心訊息
On December 31, 2023, a Schedule 13G filing was made with the United States Securities and Exchange Commission by Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia, collectively holding a 6.75% stake in Reneo Pharmaceuticals, Inc. The filing indicates that Octagon Capital Advisors LP, a Delaware limited partnership, and Octagon Investments Master Fund LP, an exempted limited partnership established in the Cayman Islands, are managed by Ting Jia, who is also the principal beneficial owner. The shares are held for investment purposes, and the filing asserts that the acquisition of the shares does not aim to change the control of Reneo Pharmaceuticals. The 2,250,000 common shares owned represent a significant investment in the company, based on the total number of shares outstanding as reported in Reneo Pharmaceuticals' Form 10-Q filed on November 13, 2023.
On December 31, 2023, a Schedule 13G filing was made with the United States Securities and Exchange Commission by Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia, collectively holding a 6.75% stake in Reneo Pharmaceuticals, Inc. The filing indicates that Octagon Capital Advisors LP, a Delaware limited partnership, and Octagon Investments Master Fund LP, an exempted limited partnership established in the Cayman Islands, are managed by Ting Jia, who is also the principal beneficial owner. The shares are held for investment purposes, and the filing asserts that the acquisition of the shares does not aim to change the control of Reneo Pharmaceuticals. The 2,250,000 common shares owned represent a significant investment in the company, based on the total number of shares outstanding as reported in Reneo Pharmaceuticals' Form 10-Q filed on November 13, 2023.
2023年12月31日，Octagon Capital Advisors LP、Octagon Investments Master Fund LP和Ting Jia共同持有Reneo Pharmicals, Inc.6.75％的股份，向美國證券交易委員會提交了附表13G申報。該文件顯示，特拉華州有限合夥企業Octagon Capital Advisors LP和在開曼群島成立的豁免有限合夥企業Octagon Investments Master Fund LP由Ting Jia管理，他也是主要受益所有人。持有這些股票是出於投資目的，該文件斷言，收購這些股份的目的並不是爲了改變Reneo Pharmicals的控制權。根據Reneo Pharmaceuticals於2023年11月13日提交的10-Q表中報告的已發行股票總數，擁有的225萬股普通股是對該公司的重大投資。
2023年12月31日，Octagon Capital Advisors LP、Octagon Investments Master Fund LP和Ting Jia共同持有Reneo Pharmicals, Inc.6.75％的股份，向美國證券交易委員會提交了附表13G申報。該文件顯示，特拉華州有限合夥企業Octagon Capital Advisors LP和在開曼群島成立的豁免有限合夥企業Octagon Investments Master Fund LP由Ting Jia管理，他也是主要受益所有人。持有這些股票是出於投資目的，該文件斷言，收購這些股份的目的並不是爲了改變Reneo Pharmicals的控制權。根據Reneo Pharmaceuticals於2023年11月13日提交的10-Q表中報告的已發行股票總數，擁有的225萬股普通股是對該公司的重大投資。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息